Spring break for biotech deals?

Deals went on spring break last week, with only two deals disclosling a potential total  value over $100 million.

Enodia Therapeutics will acquire a SEC61 inhibitor portfolio from Kezar Life Sciences Inc. (NASDAQ:KZR), including KZR-261, for $1 million up front and up to $127 million in milestones. While Enodia described the programs as preclinical, Kezar did begin a Phase I trial of the small molecule in solid tumor patients in 2021, with ClinicalTrials.gov listing the reason for termination as “sponsor decision.” Enodia already has a SEC61 platform, while Kezar is focusing on development of its immunoproteasome inhibitor zetomipzomib to treat autoimmune hepatitis...